Gastric Cancer

Business

Piper Sandler Trims Price Target for Black Diamond Therapeutics Amid Model Review, Despite Recent Clinical Wins

Analyst Piper Sandler has lowered its price target on Black Diamond Therapeutics (BDTX) while maintaining an Overweight rating, following a broad review of its biotech coverage. The adjustment comes even as the company recently reported encouraging Phase 2 data for its lead oncology drug candidate.

Feb 2, 2026

Business

ImmunityBio's Anktiva Shows Blockbuster Potential as Piper Sandler Eyes Label Expansion After QUILT Trial Data

Piper Sandler raises its price target on ImmunityBio, citing a near 700% surge in Anktiva sales and promising interim data from the QUILT trials that could support a major label expansion by 2027.

Feb 2, 2026

Business

Janux Therapeutics Downgraded as Key Drug Data Gaps Raise Platform Concerns

Clear Street downgrades Janux Therapeutics (JANX) to Hold, slashing its price target amid concerns over a lack of durability data for its lead candidate JANX007 and rising competitive pressures, despite a recent major collaboration deal with Bristol Myers Squibb.

Feb 2, 2026

Business

Kura Oncology Eyes 2026 as Pivotal Year Amid Pipeline Expansion and Analyst Scrutiny

Following a price target adjustment by Leerink Partners, Kura Oncology (KURA) is drawing investor focus to its 2026 clinical milestones and commercial strategy for its newly launched AML drug, ziftomenib.

Feb 2, 2026

World

Rafah Crossing Reopens Under Fragile Ceasefire, Offering Glimmer of Hope for Gaza's Medically Vulnerable

The Rafah border crossing between Gaza and Egypt has partially reopened under the terms of the US-brokered ceasefire, permitting a limited number of medical evacuations for the first time in nearly two years, as tens of thousands await passage.

Feb 2, 2026

Business

Quince Therapeutics Plummets After Late-Stage Trial of A-T Therapy Fails to Hit Targets

Quince Therapeutics' lead candidate, eDSP, has failed to meet primary and secondary endpoints in its pivotal Phase III NEAT trial for the rare neurological disorder Ataxia-Telangiectasia (A-T), triggering a catastrophic drop in the company's share price.

Feb 2, 2026

US

Government Shutdown Looms, Grammys Spotlight Immigration as Protests Sweep Nation

A partial government shutdown triggers furloughs, the Grammys become a platform for political statements, and nationwide protests over immigration policy unfold amid a severe winter storm's aftermath.

Feb 2, 2026

Business

Eli Lilly Bets Nearly $2 Billion on Repertoire Immune Medicines to Pioneer Next-Generation Autoimmune Therapies

Pharmaceutical giant Eli Lilly enters a strategic collaboration potentially worth up to $1.93 billion with biotech firm Repertoire Immune Medicines, aiming to develop precision treatments for autoimmune diseases that move beyond broad immunosuppression.

Feb 2, 2026

Business

Cogent Biosciences Gains Key FDA Designations for Bezuclastinib, Spotlighting GIST Treatment Potential

Cogent Biosciences secures FDA Breakthrough Therapy Designation and enters the Real-Time Oncology Review program for its lead drug candidate bezuclastinib in gastrointestinal stromal tumors (GIST), marking significant regulatory momentum for the biotech firm.

Feb 2, 2026

Business

Wall Street's Uncomfortable Truth: Three High-Profile Stocks Analysts Are Quietly Souring On

In a rare break from Wall Street's typically optimistic consensus, a handful of prominent stocks are receiving bearish price targets that signal deep-seated concerns. We examine the challenges facing Deckers, MSC Industrial, and Guardant Health, and why investors might want to look elsewhere.

Feb 2, 2026

Business

Immunocore's Valuation Puzzle: Short-Term Volatility Masks Long-Term Promise

Immunocore Holdings (IMCR) shares have experienced notable turbulence, declining over 7% in a week. Yet, a significant gap between its current price and analyst fair value estimates highlights a debate over the biotech's future, heavily reliant on its lead asset KIMMTRAK and pipeline execution.

Feb 2, 2026

Business

FDA Grants Breakthrough Status to Cogent Biosciences' GIST Combo Therapy, Accelerating Path to Market

Cogent Biosciences secures a key FDA Breakthrough Therapy Designation for its bezuclastinib-sunitinib combination in advanced GIST, following promising Phase 3 data that showed a halving of disease progression risk.

Feb 2, 2026

Business

Beyond Humira: How AbbVie Plans to Reign as a Biopharma Powerhouse by 2031

With its blockbuster Humira era in the rearview, AbbVie is betting big on its next-generation immunology drugs and a deep pipeline to drive growth and maintain its crown among Dividend Kings.

Feb 2, 2026

World

Rafah Crossing Reopens Under Fragile Gaza Ceasefire, Allowing Limited Movement

The vital Rafah border crossing between Gaza and Egypt reopened Monday for strictly limited passenger traffic, marking a tentative step in the implementation of the Israel-Hamas ceasefire. The move, described as largely symbolic for now, offers a glimmer of hope for thousands of Palestinians seeking medical care or a return home.

Feb 2, 2026

Business

February's Investment Spotlight: Three Stocks Poised for Growth in 2026

As markets navigate a new year, analysts are eyeing potential outperformers. Amazon, BeOne Medicines, and Enterprise Products Partners emerge as compelling picks, each backed by distinct catalysts from AI to biotech breakthroughs.

Feb 2, 2026

World

Rafah Crossing Reopens Under Fragile Truce, Offering Glimmer of Hope for Gaza

The Rafah border crossing between Gaza and Egypt reopened Monday for strictly limited passenger traffic, marking a critical, if symbolic, step in implementing the U.S.-brokered ceasefire. The move follows intense diplomatic efforts and comes as the agreement enters a more complex second phase.

Feb 2, 2026

World

Rafah Crossing to Reopen Under Strict Limits, Easing Gaza Exodus but Raising New Questions

Israel is set to partially reopen the Rafah border crossing with Egypt, allowing limited pedestrian movement for Palestinians. The move, a condition of the U.S.-brokered ceasefire, comes amid ongoing tensions and a continued ban on foreign journalists.

Feb 2, 2026

Business

Exelixis Stock: A Biotech Winner's Valuation Puzzle After Years of Stellar Gains

Exelixis shares have delivered impressive multi-year returns, but recent price weakness has investors questioning if the rally has run its course. A deep dive into valuation models suggests the stock may still be significantly undervalued, presenting a potential opportunity amidst market uncertainty.

Feb 2, 2026

Business

Insider Bets on Asia's Growth Engines: Techwing, Graphy, and Nanjing Leads Biolabs in Focus

Amidst a cautiously optimistic Asian market, companies where executives and directors hold significant stakes are drawing investor attention. We examine three high-conviction plays in semiconductors, 3D printing, and biotech where insider ownership aligns with explosive growth forecasts.

Feb 2, 2026

Business

IDEAYA Biosciences: A Buying Opportunity After the Pullback, or Priced for Perfection?

IDEAYA Biosciences shares have retreated from recent highs, presenting investors with a dilemma. While long-term performance remains strong, its premium valuation and significant net losses raise questions about whether the current price already reflects its promising pipeline.

Feb 2, 2026